This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Sherwin-Williams Gains on Valspar Buyout & Expansion Moves
by Zacks Equity Research
Sherwin-Williams (SHW) gains from significant synergies from the Valspar acquisition and growth through retail expansion.
Westlake Chemical to Gain on Acquisitions & Strong Demand
by Zacks Equity Research
Westlake Chemical (WLK) witnesses higher demand for major products amid raw material cost inflation and outages.
Why Should You Add Innospec (IOSP) Stock to Your Portfolio?
by Anindya Barman
Let's see what makes Innospec (IOSP) stock an attractive investment option at the moment.
POSCO Rides on Business Expansion Amid Volatile Exchange Rate
by Zacks Equity Research
POSCO's (PKX) performance will likely be affected by volatile exchange rate, despite focus on mergers and business expansion, strong demand and improvement in steel export.
Ashland (ASH) Releases Update on Fiscal 2019 Financial View
by Zacks Equity Research
Ashland (ASH) projects adjusted EPS for fiscal 2019 in the range of $3.10-$3.40, reflecting the pending divestiture of the Composites unit and the BDO manufacturing facility.
Reasons to Add Ingevity (NGVT) Stocks to Your Portfolio Now
by Zacks Equity Research
Solid growth prospects and upbeat outlook make Ingevity (NGVT) an attractive investment option.
ICL or NGVT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ICL vs. NGVT: Which Stock Is the Better Value Option?
Ingevity (NGVT) Shares Up 17% YTD: What's Working in Favor?
by Anindya Barman
Let's take a look into the factors that are driving Ingevity (NGVT).
Ingevity (NGVT) to Buy Perstorp's Capa Caprolactone Unit
by Zacks Equity Research
Ingevity (NGVT) expects the acquisition to be immediately accretive to earnings in the first full year.
CE vs. NGVT: Which Stock Is the Better Value Option?
by Zacks Equity Research
CE vs. NGVT: Which Stock Is the Better Value Option?
LyondellBasell's Technology Selected for PP Plant in China
by Zacks Equity Research
LyondellBasell's (LYB) latest project marks the ninth Spherizone line license in China.
Ashland (ASH) Wraps Up HEC Expansion, Boosts Production
by Zacks Equity Research
Capacity expansion enables Ashland (ASH) to support increasing demand for Natrosol HEC.
Newmont Provides Updated Production & Cost Guidance for FY19
by Zacks Equity Research
Newmont (NEM) expects production in 2019 to be driven by higher grade production from the Subika Underground project in Africa.
Eastman Chemical's (EMN) Board Announces 11% Hike in Dividend
by Zacks Equity Research
Eastman Chemical (EMN) is committed towards balanced and disciplined capital allocation and shareholders returns.
Here's Why You Should Buy Celanese (CE) Stock Right Now
by Anindya Barman
Let's see what makes Celanese (CE) stock an attractive investment option at the moment.
Ingevity Starts Activated Carbon Production at Changshu Plant
by Zacks Equity Research
The new facility at Changshu allows Ingevity (NGVT) to meet the rising global demand for pelletized carbon products.
Here's Why You Should Hold Commercial Metals in Your Portfolio
by Zacks Equity Research
Commercial Metals (CMC) will benefit from improvement in farm equipment manufacturing activity, construction machinery and energy related spending.
Mosaic (MOS) Up 20% in 6 Months: What's Behind the Rally?
by Zacks Equity Research
Upbeat earnings outlook, bright prospects from the Vale Fertilizantes buyout and strong fertilizer market fundamentals drive Mosaic's (MOS) shares.
Ashland (ASH) Up 15% in a Year: What's Working in Favor?
by Anindya Barman
Strategic initiatives have contributed to the gain in Ashland's (ASH) shares.
Reasons to Hold International Flavors (IFF) in Your Portfolio
by Zacks Equity Research
International Flavors' (IFF) performance is likely to be supported by growth in the global market for flavors and fragrances despite adverse impacts of rising costs.
Here's Why Ingevity (NGVT) Stock is Worth Buying Right Now
by Anindya Barman
Let's see what makes Ingevity (NGVT) stock an attractive investment option at the moment.
US Specialty Chemicals Volumes Up in October: 3 Stocks to Buy
by Anindya Barman
While specialty chemical companies face headwinds from trade tensions and raw material inflation, they should gain from healthy end-market demand and strategic initiatives.
5 Reasons to Add Ingevity (NGVT) Stock to Your Portfolio Now
by Anindya Barman
Strong growth prospects and upbeat outlook make Ingevity (NGVT) an attractive investment option.
CE or NGVT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CE vs. NGVT: Which Stock Is the Better Value Option?
Ingevity (NGVT) Up 16% in 6 Months: What's Driving the Stock?
by Anindya Barman
Forecast-topping earnings performance and upbeat outlook have contributed to the gain in Ingevity's (NGVT) shares.